Search

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.

… Monday, January 22, 2018 When the Tri-Institutional Therapeutics Discovery Institute launched just over four years ago, nothing like it existed in academia. The nonprofit academic corporation – a joint venture between Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell

Animal model research from MSK has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.

… Friday, June 14, 2024 Periods of fasting reprogram the immune system’s natural killer cells to better fight cancer, according to a new study in mice from researchers at Memorial Sloan Kettering Cancer Center (MSK). Fasting and other dietary regimens are increasingly being explored as ways to starve cancer

Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.

… Monday, January 29, 2018 Summary Doctors at MSK are at the forefront of developing treatment strategies that target the androgen receptor. This hormone drives the growth of many triple-negative breast cancers. For many people with breast cancer , drugs that target proteins driving the cancer’s growth

Ten scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 15, 2024, as part of Memorial Sloan Kettering’s 45th annual academic convocation.

… Monday, May 13, 2024 On May 15, 2024, 10 newly minted PhD scientists will officially be granted their degrees from the  Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK)  . The graduates will receive their diplomas as part of the 45th annual academic convocation and commencement ceremony

Scientists are looking to exploit defects in DNA repair as an Achilles’ heel in cancer.

… Friday, December 9, 2016 Summary Mistakes in DNA repair can lead to cancer. But they also present opportunities for treatment. Today at the San Antonio Breast Cancer Symposium, MSK Radiation Oncology Chair Simon Powell discusses new DNA repair–targeting treatments coming down the pipeline. Thousands

At any given time, close to 700 teenagers and young adults are in active treatment at Memorial Sloan Kettering. On March 18, MSK opened a hip new space dubbed the Lounge as part of the newly launched Teen and Young Adult Program designed to give these young patients the support they need during a turbulent time.

… Tuesday, March 22, 2016 Summary At any given time, close to 700 teenagers and young adults are in active treatment at Memorial Sloan Kettering. On March 18, MSK opened a hip new space dubbed the Lounge as part of the newly launched Teen and Young Adult Program designed to give patients 16-28 years of

Topical minoxidil can be of significant benefit to women with breast cancer who develop alopecia during treatment with endocrine therapies, our most recent research shows.

… Wednesday, May 16, 2018 Topical minoxidil can be of significant benefit to women with breast cancer who develop alopecia during treatment with endocrine therapies, our most recent research shows. In the study, published in JAMA Dermatology , (1)) we identified alopecia with a similar pattern to the androgenetic

Meet the four young ambassadors featured in the annual Stop & Shop campaign to fundraise for the Department of Pediatrics at Memorial Sloan Kettering.

… Monday, June 11, 2018 Summary For nearly 20 years, Memorial Sloan Kettering has partnered with Stop & Shop supermarkets to raise funds for pediatric cancer research. Meet the four spunky kids representing MSK across New York, New Jersey, and Connecticut for this year’s campaign. The next time you visit

A phase 3 trial for myelofibrosis found that adding pelabresib to ruxolitinib was more effective than ruxolitinib alone and did not significantly increase side effects.

… Tuesday, April 29, 2025 An international phase 3 clinical trial of a new drug combination for treating the blood cancer  myelofibrosis found that adding a second, experimental drug to standard treatment was more effective than the standard treatment alone. Further, adding the second drug did not significantly

New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.

… Thursday, February 27, 2014 New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain. Published in the February 27 issue of Cell , the study found that tumor cells that reach the brain — and successfully